Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer

被引：0
|
作者：
El-Rayes B
Shields, A.
Zalupski, M.
Bekaii-Saab, T.
Heilbrun, L.
Vaishampayan, U.
Manza, S.
机构：
[1] Karmanos Canc Ctr, Dearborn, MI USA
[2] Univ Michigan, Detroit, MI USA
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [21] A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer.
    El-Rayes, B. F.
    Shields, A. F.
    Vaishampayan, U.
    Heilbrun, L. K.
    Zalupski, M. M.
    Philip, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [22] Phase II Trial of Gemcitabine, Irinotecan, and Celecoxib in Patients With Advanced Pancreatic Cancer
    Lipton, Allan
    Campbell-Baird, Cynthia
    Witters, Lois
    Harvey, Harold
    Ali, Suhail
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2010, 44 (04) : 286 - 288
  • [23] A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer
    Chen, Emerson Y.
    Blanke, Charles D.
    Haller, Daniel G.
    Benson, Al B.
    Dragovich, Tomislav
    Lenz, Heinz-Josef
    Robles, Carlos
    Li, Hong
    Mori, Motomi
    Mattek, Nora
    Sanborn, Rachel E.
    Lopez, Charles D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (12): : 1193 - 1198
  • [24] Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
    Moehler, Markus
    Sprinzl, Martin F.
    Abdelfattah, Murad
    Schimanski, Carl C.
    Adami, Bernd
    Godderz, Werner
    Majer, Klaus
    Flieger, Dimitri
    Teufel, Andreas
    Siebler, Juergen
    Hoehler, Thomas
    Galle, Peter R.
    Kanzler, Stephan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (04) : 449 - 456
  • [25] Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients
    Markus Moehler
    Martin F Sprinzl
    Murad Abdelfattah
    Carl C Schimanski
    Bernd Adami
    Werner Godderz
    Klaus Majer
    Dimitri Flieger
    Andreas Teufel
    Juergen Siebler
    Thomas Hoehler
    Peter R Galle
    Stephan Kanzler
    World Journal of Gastroenterology, 2009, 15 (04) : 449 - 456
  • [26] A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer
    Kato, Takeshi
    Mishima, Hideyuki
    Ikenaga, Masakazu
    Murata, Kouhei
    Ishida, Hideyuki
    Fukunaga, Mutsumi
    Ota, Hirofumi
    Tominaga, Shusei
    Ohnishi, Tadashi
    Amano, Masahiro
    Ikeda, Kimimasa
    Ikeda, Masataka
    Sekimoto, Mitsugu
    Sakamoto, Junichi
    Monden, Morito
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (02) : 275 - 281
  • [27] First-line Treatment With Capecitabine Combined With Irinotecan in Patients With Advanced Colorectal Carcinoma A Phase II Study
    Assy, Nimer
    Basher, Walid
    Chetver, Lika
    Shnaider, Julia
    Zidan, Jamal
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (04) : E27 - E30
  • [28] A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer
    Takeshi Kato
    Hideyuki Mishima
    Masakazu Ikenaga
    Kouhei Murata
    Hideyuki Ishida
    Mutsumi Fukunaga
    Hirofumi Ota
    Shusei Tominaga
    Tadashi Ohnishi
    Masahiro Amano
    Kimimasa Ikeda
    Masataka Ikeda
    Mitsugu Sekimoto
    Junichi Sakamoto
    Morito Monden
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 275 - 281
  • [29] A Phase I/II Study of Trimetrexate and Capecitabine in Patients With Advanced Refractory Colorectal Cancer
    Matin, K
    Jacobs, SA
    Richards, T
    Wong, MK
    Earle, M
    Evans, T
    Troetschel, M
    Ferri, W
    Friedland, D
    Pinkerton, R
    Volkin, R
    Wieand, S
    Ramanathan, RK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (05): : 439 - 444
  • [30] A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
    Matsuda, Chu
    Kudo, Toshihiro
    Morimoto, Yoshihiro
    Kagawa, Yoshinori
    Tei, Mitsuyoshi
    Ide, Yoshihito
    Miyoshi, Norikatsu
    Takahashi, Hidekazu
    Uemura, Mamoru
    Takemasa, Ichiro
    Satoh, Taroh
    Mizushima, Tsunekazu
    Murata, Kohei
    Doki, Yuichiro
    Eguchi, Hidetoshi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (01): : 81 - 90
12345